The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Psychedelic Drugs-Global Market Insights and Sales Trends 2025
Synopsis
The global Psychedelic Drugs market size is expected to reach US$ million by 2029, growing at a CAGR of % from 2023 to 2029. The market is mainly driven by the significant applications of Psychedelic Drugs in various end use industries. The expanding demands from the Depressive Disorders, Post-Traumatic Stress Disorders, Substance Abuse Disorders and Obsessive Compulsive Disorders, are propelling Psychedelic Drugs market. Psilocybin, one of the segments analysed in this report, is projected to record % CAGR and reach US$ million by the end of the analysis period. Growth in the LSD segment is estimated at % CAGR for the next seven-year period.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Report Objectives
This report provides market insight on the different segments, by players, by Type, by Application. Market size and forecast (2018-2029) has been provided in the report. The primary objectives of this report are to provide 1) global market size and forecasts, growth rates, market dynamics, industry structure and developments, market situation, trends; 2) global market share and ranking by company; 3) comprehensive presentation of the global market for Psychedelic Drugs, with both quantitative and qualitative analysis through detailed segmentation; 4) detailed value chain analysis and review of growth factors essential for the existing market players and new entrants; 5) emerging opportunities in the market and the future impact of major drivers and restraints of the market.
Key Features of The Study:
This report provides in-depth analysis of the global Psychedelic Drugs market, and provides market size (US$ million) and CAGR for the forecast period (2023-2029), considering 2022 as the base year.
This report profiles key players in the global Psychedelic Drugs market based on the following parameters - company details (found date, headquarters, manufacturing bases), products portfolio, Psychedelic Drugs sales data, market share and ranking.
This report elucidates potential market opportunities across different segments and explains attractive investment proposition matrices for this market.
This report illustrates key insights about market drivers, restraints, opportunities, market trends, regional outlook.
Key companies of Psychedelic Drugs covered in this report include COMPASS Pathways PLC, Pfizer, Eli Lilly, GlaxoSmithKline, Cybin Inc, Field Trip Health, ATAI Life Sciences, NUMINUS WELLNESS and MindMed, etc.
The global Psychedelic Drugs market report caters to various stakeholders in this industry including investors, suppliers, product players, distributors, new entrants, and financial analysts.
Market Segmentation
Company Profiles:
COMPASS Pathways PLC
Pfizer
Eli Lilly
GlaxoSmithKline
Cybin Inc
Field Trip Health
ATAI Life Sciences
NUMINUS WELLNESS
MindMed
HAVN Life Sciences
Seelos Therapeutics
Jannsen
Acadia Pharmaceuticals
Intellipharmaceutics
Revive Therapeutics
Mydecine Innovations Group
Red Light Holland
Braxia Scientific
Mind Cure Health
Entheon Biomedical
Global Psychedelic Drugs market, by region:
North America (U.S., Canada, Mexico)
Europe (Germany, France, UK, Italy, etc.)
Asia Pacific (China, Japan, South Korea, Southeast Asia, India, etc.)
South America (Brazil, etc.)
Middle East and Africa (Turkey, GCC Countries, Africa, etc.)
Global Psychedelic Drugs market, Segment by Type:
Psilocybin
LSD
MDMA
DMT
Ketamine
Others
Global Psychedelic Drugs market, by Application
Depressive Disorders
Post-Traumatic Stress Disorders
Substance Abuse Disorders
Obsessive Compulsive Disorders
Others
Core Chapters
Chapter One: Introduces the report scope of the report, executive summary of global and regional market size and CAGR for the history and forecast period (2018-2023, 2024-2029). It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter Two: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter Three: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter Four: Detailed analysis of Psychedelic Drugs companies’ competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter Five: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product introduction, revenue, recent development, etc.
Chapter Six, Seven, Eight, Nine and Ten: North America, Europe, Asia Pacific, Latin America, Middle East & Africa, revenue by country.
Chapter Eleven: this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter Twelve: Research Finding/Conclusion
The global Psychedelic Drugs market size is expected to reach US$ million by 2029, growing at a CAGR of % from 2023 to 2029. The market is mainly driven by the significant applications of Psychedelic Drugs in various end use industries. The expanding demands from the Depressive Disorders, Post-Traumatic Stress Disorders, Substance Abuse Disorders and Obsessive Compulsive Disorders, are propelling Psychedelic Drugs market. Psilocybin, one of the segments analysed in this report, is projected to record % CAGR and reach US$ million by the end of the analysis period. Growth in the LSD segment is estimated at % CAGR for the next seven-year period.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Report Objectives
This report provides market insight on the different segments, by players, by Type, by Application. Market size and forecast (2018-2029) has been provided in the report. The primary objectives of this report are to provide 1) global market size and forecasts, growth rates, market dynamics, industry structure and developments, market situation, trends; 2) global market share and ranking by company; 3) comprehensive presentation of the global market for Psychedelic Drugs, with both quantitative and qualitative analysis through detailed segmentation; 4) detailed value chain analysis and review of growth factors essential for the existing market players and new entrants; 5) emerging opportunities in the market and the future impact of major drivers and restraints of the market.
Key Features of The Study:
This report provides in-depth analysis of the global Psychedelic Drugs market, and provides market size (US$ million) and CAGR for the forecast period (2023-2029), considering 2022 as the base year.
This report profiles key players in the global Psychedelic Drugs market based on the following parameters - company details (found date, headquarters, manufacturing bases), products portfolio, Psychedelic Drugs sales data, market share and ranking.
This report elucidates potential market opportunities across different segments and explains attractive investment proposition matrices for this market.
This report illustrates key insights about market drivers, restraints, opportunities, market trends, regional outlook.
Key companies of Psychedelic Drugs covered in this report include COMPASS Pathways PLC, Pfizer, Eli Lilly, GlaxoSmithKline, Cybin Inc, Field Trip Health, ATAI Life Sciences, NUMINUS WELLNESS and MindMed, etc.
The global Psychedelic Drugs market report caters to various stakeholders in this industry including investors, suppliers, product players, distributors, new entrants, and financial analysts.
Market Segmentation
Company Profiles:
COMPASS Pathways PLC
Pfizer
Eli Lilly
GlaxoSmithKline
Cybin Inc
Field Trip Health
ATAI Life Sciences
NUMINUS WELLNESS
MindMed
HAVN Life Sciences
Seelos Therapeutics
Jannsen
Acadia Pharmaceuticals
Intellipharmaceutics
Revive Therapeutics
Mydecine Innovations Group
Red Light Holland
Braxia Scientific
Mind Cure Health
Entheon Biomedical
Global Psychedelic Drugs market, by region:
North America (U.S., Canada, Mexico)
Europe (Germany, France, UK, Italy, etc.)
Asia Pacific (China, Japan, South Korea, Southeast Asia, India, etc.)
South America (Brazil, etc.)
Middle East and Africa (Turkey, GCC Countries, Africa, etc.)
Global Psychedelic Drugs market, Segment by Type:
Psilocybin
LSD
MDMA
DMT
Ketamine
Others
Global Psychedelic Drugs market, by Application
Depressive Disorders
Post-Traumatic Stress Disorders
Substance Abuse Disorders
Obsessive Compulsive Disorders
Others
Core Chapters
Chapter One: Introduces the report scope of the report, executive summary of global and regional market size and CAGR for the history and forecast period (2018-2023, 2024-2029). It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter Two: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter Three: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter Four: Detailed analysis of Psychedelic Drugs companies’ competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter Five: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product introduction, revenue, recent development, etc.
Chapter Six, Seven, Eight, Nine and Ten: North America, Europe, Asia Pacific, Latin America, Middle East & Africa, revenue by country.
Chapter Eleven: this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter Twelve: Research Finding/Conclusion
Index1 Market Overview of Psychedelic Drugs
1.1 Psychedelic Drugs Market Overview
1.1.1 Psychedelic Drugs Product Scope
1.1.2 Psychedelic Drugs Market Status and Outlook
1.2 Global Psychedelic Drugs Market Size Overview by Region 2018 VS 2022 VS 2029
1.3 Global Psychedelic Drugs Market Size by Region (2018-2029)
1.4 Global Psychedelic Drugs Historic Market Size by Region (2018-2023)
1.5 Global Psychedelic Drugs Market Size Forecast by Region (2024-2029)
1.6 Key Regions, Psychedelic Drugs Market Size (2018-2029)
1.6.1 North America Psychedelic Drugs Market Size (2018-2029)
1.6.2 Europe Psychedelic Drugs Market Size (2018-2029)
1.6.3 Asia-Pacific Psychedelic Drugs Market Size (2018-2029)
1.6.4 Latin America Psychedelic Drugs Market Size (2018-2029)
1.6.5 Middle East & Africa Psychedelic Drugs Market Size (2018-2029)
2 Psychedelic Drugs Market by Type
2.1 Introduction
2.1.1 Psilocybin
2.1.2 LSD
2.1.3 MDMA
2.1.4 DMT
2.1.5 Ketamine
2.1.6 Others
2.2 Global Psychedelic Drugs Market Size by Type: 2018 VS 2022 VS 2029
2.2.1 Global Psychedelic Drugs Historic Market Size by Type (2018-2023)
2.2.2 Global Psychedelic Drugs Forecasted Market Size by Type (2024-2029)
2.3 Key Regions Market Size by Type
2.3.1 North America Psychedelic Drugs Revenue Breakdown by Type (2018-2029)
2.3.2 Europe Psychedelic Drugs Revenue Breakdown by Type (2018-2029)
2.3.3 Asia-Pacific Psychedelic Drugs Revenue Breakdown by Type (2018-2029)
2.3.4 Latin America Psychedelic Drugs Revenue Breakdown by Type (2018-2029)
2.3.5 Middle East and Africa Psychedelic Drugs Revenue Breakdown by Type (2018-2029)
3 Psychedelic Drugs Market Overview by Application
3.1 Introduction
3.1.1 Depressive Disorders
3.1.2 Post-Traumatic Stress Disorders
3.1.3 Substance Abuse Disorders
3.1.4 Obsessive Compulsive Disorders
3.1.5 Others
3.2 Global Psychedelic Drugs Market Size by Application: 2018 VS 2022 VS 2029
3.2.1 Global Psychedelic Drugs Historic Market Size by Application (2018-2023)
3.2.2 Global Psychedelic Drugs Forecasted Market Size by Application (2024-2029)
3.3 Key Regions Market Size by Application
3.3.1 North America Psychedelic Drugs Revenue Breakdown by Application (2018-2029)
3.3.2 Europe Psychedelic Drugs Revenue Breakdown by Application (2018-2029)
3.3.3 Asia-Pacific Psychedelic Drugs Revenue Breakdown by Application (2018-2029)
3.3.4 Latin America Psychedelic Drugs Revenue Breakdown by Application (2018-2029)
3.3.5 Middle East and Africa Psychedelic Drugs Revenue Breakdown by Application (2018-2029)
4 Psychedelic Drugs Competition Analysis by Players
4.1 Global Psychedelic Drugs Market Size by Players (2018-2023)
4.2 Global Top Players by Company Type (Tier 1, Tier 2 and Tier 3) & (based on the Revenue in Psychedelic Drugs as of 2022)
4.3 Date of Key Players Enter into Psychedelic Drugs Market
4.4 Global Top Players Psychedelic Drugs Headquarters and Area Served
4.5 Key Players Psychedelic Drugs Product Solution and Service
4.6 Competitive Status
4.6.1 Psychedelic Drugs Market Concentration Rate
4.6.2 Mergers & Acquisitions, Expansion Plans
5 Company (Top Players) Profiles
5.1 COMPASS Pathways PLC
5.1.1 COMPASS Pathways PLC Profile
5.1.2 COMPASS Pathways PLC Main Business
5.1.3 COMPASS Pathways PLC Psychedelic Drugs Products, Services and Solutions
5.1.4 COMPASS Pathways PLC Psychedelic Drugs Revenue (US$ Million) & (2018-2023)
5.1.5 COMPASS Pathways PLC Recent Developments
5.2 Pfizer
5.2.1 Pfizer Profile
5.2.2 Pfizer Main Business
5.2.3 Pfizer Psychedelic Drugs Products, Services and Solutions
5.2.4 Pfizer Psychedelic Drugs Revenue (US$ Million) & (2018-2023)
5.2.5 Pfizer Recent Developments
5.3 Eli Lilly
5.3.1 Eli Lilly Profile
5.3.2 Eli Lilly Main Business
5.3.3 Eli Lilly Psychedelic Drugs Products, Services and Solutions
5.3.4 Eli Lilly Psychedelic Drugs Revenue (US$ Million) & (2018-2023)
5.3.5 GlaxoSmithKline Recent Developments
5.4 GlaxoSmithKline
5.4.1 GlaxoSmithKline Profile
5.4.2 GlaxoSmithKline Main Business
5.4.3 GlaxoSmithKline Psychedelic Drugs Products, Services and Solutions
5.4.4 GlaxoSmithKline Psychedelic Drugs Revenue (US$ Million) & (2018-2023)
5.4.5 GlaxoSmithKline Recent Developments
5.5 Cybin Inc
5.5.1 Cybin Inc Profile
5.5.2 Cybin Inc Main Business
5.5.3 Cybin Inc Psychedelic Drugs Products, Services and Solutions
5.5.4 Cybin Inc Psychedelic Drugs Revenue (US$ Million) & (2018-2023)
5.5.5 Cybin Inc Recent Developments
5.6 Field Trip Health
5.6.1 Field Trip Health Profile
5.6.2 Field Trip Health Main Business
5.6.3 Field Trip Health Psychedelic Drugs Products, Services and Solutions
5.6.4 Field Trip Health Psychedelic Drugs Revenue (US$ Million) & (2018-2023)
5.6.5 Field Trip Health Recent Developments
5.7 ATAI Life Sciences
5.7.1 ATAI Life Sciences Profile
5.7.2 ATAI Life Sciences Main Business
5.7.3 ATAI Life Sciences Psychedelic Drugs Products, Services and Solutions
5.7.4 ATAI Life Sciences Psychedelic Drugs Revenue (US$ Million) & (2018-2023)
5.7.5 ATAI Life Sciences Recent Developments
5.8 NUMINUS WELLNESS
5.8.1 NUMINUS WELLNESS Profile
5.8.2 NUMINUS WELLNESS Main Business
5.8.3 NUMINUS WELLNESS Psychedelic Drugs Products, Services and Solutions
5.8.4 NUMINUS WELLNESS Psychedelic Drugs Revenue (US$ Million) & (2018-2023)
5.8.5 NUMINUS WELLNESS Recent Developments
5.9 MindMed
5.9.1 MindMed Profile
5.9.2 MindMed Main Business
5.9.3 MindMed Psychedelic Drugs Products, Services and Solutions
5.9.4 MindMed Psychedelic Drugs Revenue (US$ Million) & (2018-2023)
5.9.5 MindMed Recent Developments
5.10 HAVN Life Sciences
5.10.1 HAVN Life Sciences Profile
5.10.2 HAVN Life Sciences Main Business
5.10.3 HAVN Life Sciences Psychedelic Drugs Products, Services and Solutions
5.10.4 HAVN Life Sciences Psychedelic Drugs Revenue (US$ Million) & (2018-2023)
5.10.5 HAVN Life Sciences Recent Developments
5.11 Seelos Therapeutics
5.11.1 Seelos Therapeutics Profile
5.11.2 Seelos Therapeutics Main Business
5.11.3 Seelos Therapeutics Psychedelic Drugs Products, Services and Solutions
5.11.4 Seelos Therapeutics Psychedelic Drugs Revenue (US$ Million) & (2018-2023)
5.11.5 Seelos Therapeutics Recent Developments
5.12 Jannsen
5.12.1 Jannsen Profile
5.12.2 Jannsen Main Business
5.12.3 Jannsen Psychedelic Drugs Products, Services and Solutions
5.12.4 Jannsen Psychedelic Drugs Revenue (US$ Million) & (2018-2023)
5.12.5 Jannsen Recent Developments
5.13 Acadia Pharmaceuticals
5.13.1 Acadia Pharmaceuticals Profile
5.13.2 Acadia Pharmaceuticals Main Business
5.13.3 Acadia Pharmaceuticals Psychedelic Drugs Products, Services and Solutions
5.13.4 Acadia Pharmaceuticals Psychedelic Drugs Revenue (US$ Million) & (2018-2023)
5.13.5 Acadia Pharmaceuticals Recent Developments
5.14 Intellipharmaceutics
5.14.1 Intellipharmaceutics Profile
5.14.2 Intellipharmaceutics Main Business
5.14.3 Intellipharmaceutics Psychedelic Drugs Products, Services and Solutions
5.14.4 Intellipharmaceutics Psychedelic Drugs Revenue (US$ Million) & (2018-2023)
5.14.5 Intellipharmaceutics Recent Developments
5.15 Revive Therapeutics
5.15.1 Revive Therapeutics Profile
5.15.2 Revive Therapeutics Main Business
5.15.3 Revive Therapeutics Psychedelic Drugs Products, Services and Solutions
5.15.4 Revive Therapeutics Psychedelic Drugs Revenue (US$ Million) & (2018-2023)
5.15.5 Revive Therapeutics Recent Developments
5.16 Mydecine Innovations Group
5.16.1 Mydecine Innovations Group Profile
5.16.2 Mydecine Innovations Group Main Business
5.16.3 Mydecine Innovations Group Psychedelic Drugs Products, Services and Solutions
5.16.4 Mydecine Innovations Group Psychedelic Drugs Revenue (US$ Million) & (2018-2023)
5.16.5 Mydecine Innovations Group Recent Developments
5.17 Red Light Holland
5.17.1 Red Light Holland Profile
5.17.2 Red Light Holland Main Business
5.17.3 Red Light Holland Psychedelic Drugs Products, Services and Solutions
5.17.4 Red Light Holland Psychedelic Drugs Revenue (US$ Million) & (2018-2023)
5.17.5 Red Light Holland Recent Developments
5.18 Braxia Scientific
5.18.1 Braxia Scientific Profile
5.18.2 Braxia Scientific Main Business
5.18.3 Braxia Scientific Psychedelic Drugs Products, Services and Solutions
5.18.4 Braxia Scientific Psychedelic Drugs Revenue (US$ Million) & (2018-2023)
5.18.5 Braxia Scientific Recent Developments
5.19 Mind Cure Health
5.19.1 Mind Cure Health Profile
5.19.2 Mind Cure Health Main Business
5.19.3 Mind Cure Health Psychedelic Drugs Products, Services and Solutions
5.19.4 Mind Cure Health Psychedelic Drugs Revenue (US$ Million) & (2018-2023)
5.19.5 Mind Cure Health Recent Developments
5.20 Entheon Biomedical
5.20.1 Entheon Biomedical Profile
5.20.2 Entheon Biomedical Main Business
5.20.3 Entheon Biomedical Psychedelic Drugs Products, Services and Solutions
5.20.4 Entheon Biomedical Psychedelic Drugs Revenue (US$ Million) & (2018-2023)
5.20.5 Entheon Biomedical Recent Developments
6 North America
6.1 North America Psychedelic Drugs Market Size by Country (2018-2029)
6.2 United States
6.3 Canada
7 Europe
7.1 Europe Psychedelic Drugs Market Size by Country (2018-2029)
7.2 Germany
7.3 France
7.4 U.K.
7.5 Italy
7.6 Russia
7.7 Nordic Countries
7.8 Rest of Europe
8 Asia-Pacific
8.1 Asia-Pacific Psychedelic Drugs Market Size by Region (2018-2029)
8.2 China
8.3 Japan
8.4 South Korea
8.5 Southeast Asia
8.6 India
8.7 Australia
8.8 Rest of Asia-Pacific
9 Latin America
9.1 Latin America Psychedelic Drugs Market Size by Country (2018-2029)
9.2 Mexico
9.3 Brazil
9.4 Rest of Latin America
10 Middle East & Africa
10.1 Middle East & Africa Psychedelic Drugs Market Size by Country (2018-2029)
10.2 Turkey
10.3 Saudi Arabia
10.4 UAE
10.5 Rest of Middle East & Africa
11 Psychedelic Drugs Market Dynamics
11.1 Psychedelic Drugs Industry Trends
11.2 Psychedelic Drugs Market Drivers
11.3 Psychedelic Drugs Market Challenges
11.4 Psychedelic Drugs Market Restraints
12 Research Finding /Conclusion
13 Methodology and Data Source
13.1 Methodology/Research Approach
13.1.1 Research Programs/Design
13.1.2 Market Size Estimation
13.1.3 Market Breakdown and Data Triangulation
13.2 Data Source
13.2.1 Secondary Sources
13.2.2 Primary Sources
13.3 Disclaimer
13.4 Author List
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
